Sign in
Taking peopleNo phase

Fosfomycin I.v. for Treatment of Severely Infected Patients

Key facts

Who runs it
Infectopharm Arzneimittel GmbH
Where
Austria, Germany, Greece, Italy, and United Kingdom50 sites in 5 countriesChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
1,000 people, planned
Started
Dec 2016
Expected to end
Dec 2030
Type of study
Observational
Record updated
1 October 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Male or female patients aged ≥ 18 years
  • Treatment with fosfomycin according to the (national) Summary of Product Characteristics (SmPC) of fosfomycin i.v
  • Patients with osteomyelitis, complicated urinary tract infection, nosocomial lower respiratory tract infection, bacterial meningitis/central nervous system infection, bacteraemia/sepsis, skin and soft tissue infection, endocarditis or other infection, each as far as covered by the respective nationally relevant SmPC
  • Written informed consent of the participant (or person in charge in case of patients incapable of giving consent)

Who cannot take part

  • Previous documentation of the patient in the present study
  • Patients with known hypersensitivity to fosfomycin or any of the excipients
  • Failure of > 3 of the following organ systems: respiratory system, nervous system, cardiovascular system, liver, coagulation, kidney
  • Manifest Human Immunodeficiency Virus (HIV) disease (Acquired Immunodeficiency Syndrome, AIDS)
  • Patients with involvement of fungi or mycobacteria in the targeted infection
  • Patients participating in an interventional clinical trial
  • Terminally ill patients
  • Patients with "do not resuscitate order"
  • Palliative treatment approach
  • Fosfomycin treatment as 4th line treatment or at later stage

This trial has no sites in United States.

It has sites in 5 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this European, multicentric, prospective, non-interventional study is to document and evaluate the efficacy and safety of the treatment of severely infected patients with intravenously administered fosfomycin, including patients with osteomyelitis, complicated urinary tract infection, nosocomial lower respiratory tract infection, bacterial meningitis/central nervous system infection, bacteraemia/sepsis, skin and soft tissue infection, endocarditis or other infections, each as far as covered by the respective nationally relevant SmPC.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An International, Multicentre, Non-comparative, Non-interventional, Prospective Clinical Registry to Evaluate the Clinical Outcome and Safety of the Treatment of Severely Infected Patients with Fosfomycin I.v.
Publications
Record updated
1 October 2024